Triple therapy for type 2 diabetes and kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding dulaglutide (a weekly injection) to two medications you may already be taking—an SGLT2 inhibitor and finerenone—helps protect your kidneys and controls blood sugar better in people with type 2 diabetes and chronic kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with type 2 diabetes and chronic kidney disease
- Blood sugar control between 7.0% and 11% (HbA1c test)
- Specific level of protein in urine (UACR 300–5000 mg/g)
- Body mass index (BMI) between 21 and 45
- Already taking SGLT2 inhibitor and finerenone together for at least 3 months at full doses
- Kidney function not too severely damaged (eGFR ≥30)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if ganagliflozin, a once-daily pill, can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and manage blood sugar.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This study tests a four-drug combination to see if it can better protect the kidneys in people with type 2 diabetes and kidney disease. If you qualify, you may receive this combination therapy and be monitored for 6 months.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.